Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 501

1.

Avoiding immortal time bias in observational studies.

Suissa S, Ernst P.

Eur Respir J. 2020 Mar 20;55(3). pii: 2000138. doi: 10.1183/13993003.00138-2020. Print 2020 Mar. No abstract available.

PMID:
32198272
2.

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.

Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L.

Circulation. 2020 Feb 18;141(7):549-559. doi: 10.1161/CIRCULATIONAHA.119.044750. Epub 2020 Feb 17.

PMID:
32065766
3.

Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials.

Franklin JM, Glynn RJ, Suissa S, Schneeweiss S.

Clin Pharmacol Ther. 2020 Apr;107(4):735-737. doi: 10.1002/cpt.1793. Epub 2020 Feb 12. No abstract available.

PMID:
32052415
4.

Beta 2 agonists and the incidence of Parkinson's disease.

Giorgianni F, Ernst P, Dell'Aniello S, Suissa S, Renoux C.

Am J Epidemiol. 2020 Feb 4. pii: kwaa012. doi: 10.1093/aje/kwaa012. [Epub ahead of print]

PMID:
32016345
5.

Pioglitazone and bladder cancer: improving research methods.

Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S.

Diabet Med. 2020 Jan 29. doi: 10.1111/dme.14248. [Epub ahead of print] No abstract available.

PMID:
31995846
6.

The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.

Tran T, Šterclová M, Mogulkoc N, Lewandowska K, Müller V, Hájková M, Kramer MR, Jovanović D, Tekavec-Trkanjec J, Studnicka M, Stoeva N, Hejduk K, Dušek L, Suissa S, Vašáková M; EMPIRE registry.

Respir Res. 2020 Jan 8;21(1):11. doi: 10.1186/s12931-019-1271-z.

7.

The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the first eight years, and a look to the future.

Platt RW, Henry DA, Suissa S.

Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:103-107. doi: 10.1002/pds.4936. Epub 2019 Dec 8. No abstract available.

PMID:
31814201
8.

Improving the Efficiency of Randomized Trials: The DYNAGITO Example.

Suissa S.

COPD. 2020 Feb;17(1):4-6. doi: 10.1080/15412555.2019.1698020. Epub 2019 Dec 3.

PMID:
31793398
9.

Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.

Suissa S, Dell'Aniello S, Ernst P.

Chest. 2019 Nov 22. pii: S0012-3692(19)34225-4. doi: 10.1016/j.chest.2019.11.007. [Epub ahead of print]

PMID:
31759966
10.

Inhaled corticosteroid use and the incidence of lung cancer in COPD.

Suissa S, Dell'Aniello S, Gonzalez AV, Ernst P.

Eur Respir J. 2020 Feb 20;55(2). pii: 1901720. doi: 10.1183/13993003.01720-2019. Print 2020 Feb.

PMID:
31744837
11.

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.

Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, Suissa S, Gomez-Caminero A.

Arthritis Res Ther. 2019 Nov 8;21(1):228. doi: 10.1186/s13075-019-1992-x.

12.

Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy.

Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, Suissa S, Trifirò G.

Drug Saf. 2020 Jan;43(1):1-5. doi: 10.1007/s40264-019-00871-w. No abstract available.

PMID:
31641964
13.

Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.

Douros A, Dell'Aniello S, Yu OHY, Suissa S.

Diabetes Obes Metab. 2020 Feb;22(2):254-262. doi: 10.1111/dom.13893. Epub 2019 Nov 3.

PMID:
31596043
14.

Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.

Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P, Suissa S.

Rheumatology (Oxford). 2020 Apr 1;59(4):820-827. doi: 10.1093/rheumatology/kez359.

PMID:
31504972
15.

Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies".

Schneeweiss S, Suissa S.

Stat Med. 2019 Sep 30;38(22):4209-4212. doi: 10.1002/sim.8320. No abstract available.

PMID:
31489683
16.

Inhaled corticosteroids and pneumonia mortality in COPD patients.

Suissa S.

Eur Respir J. 2019 Sep 5;54(3). pii: 1901276. doi: 10.1183/13993003.01276-2019. Print 2019 Sep. No abstract available.

PMID:
31488588
17.

Misinterpretation of time-to-first event curves can lead to inappropriate treatment.

Suissa S, Ariel A.

Eur Respir J. 2019 Sep 5;54(3). pii: 1901275. doi: 10.1183/13993003.01275-2019. Print 2019 Sep. No abstract available.

PMID:
31488587
18.

Response.

Suissa S, Ernst P.

Chest. 2019 Aug;156(2):416-417. doi: 10.1016/j.chest.2019.04.097. No abstract available.

PMID:
31395262
19.

Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.

Filion KB, Douros A, Azoulay L, Yin H, Yu OH, Suissa S.

Br J Clin Pharmacol. 2019 Oct;85(10):2378-2389. doi: 10.1111/bcp.14056. Epub 2019 Jul 31.

PMID:
31276600
20.

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study.

Lin HD, Lai CL, Dong YH, Tu YK, Chan KA, Suissa S.

Drugs Real World Outcomes. 2019 Sep;6(3):93-104. doi: 10.1007/s40801-019-0156-2.

21.

Triple therapy in COPD: only for the right patient.

Suissa S, Ariel A.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900394. doi: 10.1183/13993003.00394-2019. Print 2019 Apr. No abstract available.

PMID:
31000667
22.

Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.

Suissa S, Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P.

Semin Arthritis Rheum. 2019 Dec;49(3):366-372. doi: 10.1016/j.semarthrit.2019.03.007. Epub 2019 Mar 16.

PMID:
30979397
23.

Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.

Suissa S, Dell'Aniello S, Ernst P.

Chest. 2019 Jun;155(6):1158-1165. doi: 10.1016/j.chest.2019.03.005. Epub 2019 Mar 26.

PMID:
30922950
24.

Risk of Malignant Cancers in Inflammatory Bowel Disease.

Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P.

J Crohns Colitis. 2019 Sep 27;13(10):1302-1310. doi: 10.1093/ecco-jcc/jjz058.

PMID:
30874294
25.

FMR1 Reactivating Treatments in Fragile X iPSC-Derived Neural Progenitors In Vitro and In Vivo.

Vershkov D, Fainstein N, Suissa S, Golan-Lev T, Ben-Hur T, Benvenisty N.

Cell Rep. 2019 Mar 5;26(10):2531-2539.e4. doi: 10.1016/j.celrep.2019.02.026.

26.

Observational Studies in COPD: Summary of Guidance for Authors.

Suissa S, Sotgiu G, Brusasco V.

COPD. 2018 Oct;15(5):415-417. doi: 10.1080/15412555.2018.1555234. No abstract available.

PMID:
30822246
27.

Beta-Blockers in COPD: A Methodological Review of the Observational Studies.

Suissa S, Ernst P.

COPD. 2018 Oct;15(5):520-525. doi: 10.1080/15412555.2018.1554637. Review.

PMID:
30822238
28.

Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.

Montastruc F, Renoux C, Hudson M, Dell'Aniello S, Simon TA, Suissa S.

Semin Arthritis Rheum. 2019 Jun;48(6):1053-1058. doi: 10.1016/j.semarthrit.2019.01.009. Epub 2019 Jan 25.

PMID:
30772001
29.

Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?

Suissa S.

Eur Respir J. 2019 Feb 14;53(2). pii: 1802112. doi: 10.1183/13993003.02112-2018. Print 2019 Feb. No abstract available.

PMID:
30765484
30.

Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.

Montastruc F, Nie R, Loo S, Rej S, Dell'Aniello S, Micallef J, Suissa S, Renoux C.

JAMA Psychiatry. 2019 Apr 1;76(4):409-417. doi: 10.1001/jamapsychiatry.2018.4149.

31.

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.

Douros A, Renoux C, Yin H, Filion KB, Suissa S, Azoulay L.

Am J Med. 2019 Feb;132(2):191-199.e12. doi: 10.1016/j.amjmed.2018.10.008. Epub 2018 Oct 25.

PMID:
30691551
32.

How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias.

Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Suissa S.

Pharmacoepidemiol Drug Saf. 2019 Jan 15. doi: 10.1002/pds.4722. [Epub ahead of print]

PMID:
30648307
33.

Triple therapy trials in COPD: a precision medicine opportunity.

Suissa S, Ariel A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801848. doi: 10.1183/13993003.01848-2018. Print 2018 Dec. No abstract available.

PMID:
30545959
34.

Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.

Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S.

Rheumatology (Oxford). 2019 Apr 1;58(4):683-691. doi: 10.1093/rheumatology/key352.

35.

A systematic review of observational studies of the association between pioglitazone use and bladder cancer.

Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S.

Diabet Med. 2019 Jan;36(1):22-35. doi: 10.1111/dme.13854. Epub 2018 Nov 15.

PMID:
30378165
36.

Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.

Suissa S, Dell'Aniello S, Ernst P.

Lancet Respir Med. 2018 Nov;6(11):855-862. doi: 10.1016/S2213-2600(18)30368-0. Epub 2018 Oct 18.

PMID:
30343028
37.

Cardiovascular disease and COPD: dangerous liaisons?

Rabe KF, Hurst JR, Suissa S.

Eur Respir Rev. 2018 Oct 3;27(149). pii: 180057. doi: 10.1183/16000617.0057-2018. Print 2018 Sep 30. Review. Erratum in: Eur Respir Rev. 2018 Nov 21;27(150):.

38.

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.

Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, Suissa S, Adjei AA, Akdis CA, Azoulay É, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL.

Ann Am Thorac Soc. 2019 Jan;16(1):22-28. doi: 10.1513/AnnalsATS.201808-564PS. No abstract available. Erratum in: Ann Am Thorac Soc. 2019 Feb;16(2):283.

39.

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S.

BMJ. 2018 Jul 18;362:k2693. doi: 10.1136/bmj.k2693.

40.

Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Suissa S.

Diabetes Care. 2018 Jun;41(6):e109-e110. doi: 10.2337/dci18-0015. No abstract available.

PMID:
29784709
41.

The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies.

Tran T, Suissa S.

Eur Respir J. 2018 Jun 21;51(6). pii: 1800376. doi: 10.1183/13993003.00376-2018. Print 2018 Jun. Review.

42.

Observational Studies of Inhaled Corticosteroid Effectiveness in COPD: Lessons Learned.

Suissa S, Ernst P.

Chest. 2018 Aug;154(2):257-265. doi: 10.1016/j.chest.2018.04.006. Epub 2018 Apr 19. Review.

PMID:
29679596
43.

Making Sense of Triple Inhaled Therapy for COPD.

Suissa S, Drazen JM.

N Engl J Med. 2018 May 3;378(18):1723-1724. doi: 10.1056/NEJMe1716802. Epub 2018 Apr 18. No abstract available.

PMID:
29669218
44.

Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.

Suissa S.

Circulation. 2018 Apr 3;137(14):1432-1434. doi: 10.1161/CIRCULATIONAHA.117.032799. No abstract available.

PMID:
29610125
45.

Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.

Huiart L, Ferdynus C, Renoux C, Beaugrand A, Lafarge S, Bruneau L, Suissa S, Maillard O, Ranouil X.

BMJ Open. 2018 Mar 30;8(3):e018180. doi: 10.1136/bmjopen-2017-018180.

46.

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C.

J Am Coll Cardiol. 2018 Mar 13;71(10):1105-1113. doi: 10.1016/j.jacc.2018.01.009.

47.

Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.

Loo SY, Coulombe J, Dell'Aniello S, Brophy JM, Suissa S, Renoux C.

BMJ Open. 2018 Jan 24;8(1):e019638. doi: 10.1136/bmjopen-2017-019638.

48.

Reply to P. Autier et al.

Suissa S, Azoulay L.

J Clin Oncol. 2018 Mar 10;36(8):831-832. doi: 10.1200/JCO.2017.77.0057. Epub 2018 Jan 25. No abstract available.

PMID:
29369706
49.

Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.

Suissa S.

Diabetes Care. 2018 Feb;41(2):219-223. doi: 10.2337/dc17-1059.

PMID:
29358464
50.

Food and Drug Administration-mandated Trials of Long-Acting β-Agonist Safety in Asthma. Bang for the Buck?

Suissa S, Israel E, Donohue J, Evans S, Kemp J.

Am J Respir Crit Care Med. 2018 Apr 15;197(8):987-990. doi: 10.1164/rccm.201709-1940PP. No abstract available.

PMID:
29357261

Supplemental Content

Loading ...
Support Center